当前位置: 首页 > 期刊 > 《风湿病与关节炎》 > 2018年第6期
编号:13300695
注射用重组人Ⅱ型肿瘤坏死因子受体—抗体融合蛋白对绝经后女性类风湿关节炎血清性激素水平的影响(4)
http://www.100md.com 2018年6月1日 《风湿病与关节炎》 2018年第6期
     [10]CUTOLO M.Androgens in rheumatoid arthritis:when are they effectors?[J].Arthritis Res Ther,2009,11(5):126.

    [11]TENGSTRAND B,CARLSTR?M K,FELL?NDER-TSAI L,et al.Abnormal levels of serum dehydroepiandrosterone,estrone,and estradiol in men with rheumatoid arthritis:high correlation between serum estradiol and current degree of inflammation[J].J Rheumatol,2003,30(11):2338-2343.

    [12]TO SQ,KNOWER KC,CLYNE CD.NFκB and MAPK signalling pathways mediate TNFα-induced Early Growth Response gene transcription leading to aromatase expression[J].Biochem Biophys Res Commun,2013,433(1):96-101.

    [13]连超峰,张奉春.重组人Ⅱ型肿瘤坏死因子受体-抗體融合蛋白治疗中重度早期类风湿关节炎和活动性脊柱关节炎的中国患者的临床观察[J].中华风湿病学杂志,2016,20(2):106-111.

    [14]刘小军,冯艳广,王俊丽,等.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合甲氨蝶呤治疗难治性类风湿关节炎15例[J].风湿病与关节炎,2013,2(8):33-35.

    [15]STRAUB RH,H?RLE P,YAMANA S,et al.Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis:a randomized,double-blind,placebo-controlled study[J].Arthritis Rheum,2006,54(6):1778-1785., 百拇医药(史丽璞 王旭 郇稳)
上一页1 2 3 4